Cargando…

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

Detalles Bibliográficos
Autores principales: Morgan, C, Jin, X, Yu, X, De Rosa, S, Kublin, J, Metch, B, Keefer, M, NIAID, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441823/
http://dx.doi.org/10.1186/1742-4690-9-S2-P133
_version_ 1782243384277073920
author Morgan, C
Jin, X
Yu, X
De Rosa, S
Kublin, J
Metch, B
Keefer, M
NIAID, H
author_facet Morgan, C
Jin, X
Yu, X
De Rosa, S
Kublin, J
Metch, B
Keefer, M
NIAID, H
author_sort Morgan, C
collection PubMed
description
format Online
Article
Text
id pubmed-3441823
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34418232012-09-18 DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials Morgan, C Jin, X Yu, X De Rosa, S Kublin, J Metch, B Keefer, M NIAID, H Retrovirology Poster Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441823/ http://dx.doi.org/10.1186/1742-4690-9-S2-P133 Text en Copyright ©2012 Morgan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Morgan, C
Jin, X
Yu, X
De Rosa, S
Kublin, J
Metch, B
Keefer, M
NIAID, H
DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title_full DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title_fullStr DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title_full_unstemmed DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title_short DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
title_sort dna plasmid hiv vaccine design, number of doses, participant gender, and body mass index affect t-cell responses across hiv vaccine clinical trials
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441823/
http://dx.doi.org/10.1186/1742-4690-9-S2-P133
work_keys_str_mv AT morganc dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT jinx dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT yux dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT derosas dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT kublinj dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT metchb dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT keeferm dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials
AT niaidh dnaplasmidhivvaccinedesignnumberofdosesparticipantgenderandbodymassindexaffecttcellresponsesacrosshivvaccineclinicaltrials